Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups

Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of molecular subtyping using MammaPrint and BluePrint in...

Full description

Saved in:
Bibliographic Details
Published in:Breast Cancer Res Treat
Main Authors: Yao, Katharine, Goldschmidt, Robert, Turk, Mary, Wesseling, Jelle, Stork-Sloots, Lisette, de Snoo, Femke, Cristofanilli, Massimo
Format: Artigo
Language:Inglês
Published: Springer US 2015
Subjects:
Clinical Trial
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4621695/
https://ncbi.nlm.nih.gov/pubmed/26424167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3587-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items